Blood Pressure Control and Nephroprotection in Diabetes

Journal of Clinical Pharmacology

Volumn 44, Issue 4, 2004, Pages 431-438

  Abbott, Kevin ^a   Basta, Emad ^b   Bakris, George L ^b  

^a USUHS/Walter Reed Army Hospital   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; Angiotensin; Diabetes; Hypertension; Nephropathy; Receptor

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDRALAZINE; IRBESARTAN; ISRADIPINE; LABETALOL; LISINOPRIL; LOSARTAN; METHYLDOPA; MINOXIDIL; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DRUG EFFICACY; DRUG INDICATION; HUMAN; HYPERTENSION; INCIDENCE; INTERNATIONAL COOPERATION; KIDNEY DISEASE; KIDNEY FUNCTION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRACTICE GUIDELINE; PULSE RATE; RISK BENEFIT ANALYSIS; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN;

EID: 1642314109     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004263046     Document Type: Conference Paper

References (54)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2): 434-444.
2. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, et al: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25(4, Pt. 1):587-594.
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334(1):13-18.
4. Cherry D, Woodwell D: National Ambulatory Medical Care Survey: 2000 Summary. Atlanta, GA: Center for Disease Control and Prevention, 2002.
5. Mailloux LU: Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001; 21(2):146-156.
6. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl. 2):B54-B64.
7. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36(3):646-661.
8. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33(5):1004-1010.
9. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7(1):35-43.
10. Remuzzi G: Renal protection: progression, regression, remission from nephropathy beyond blood pressure control. Int J Clin Pract Suppl 2000;110:9-15.
11. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157(21):2413-2446.
12. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 1999;17(2):151-183.
13. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1-S231.
14. American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002;25(Suppl. 1):S1-S147.
15. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-869.
16. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21(4):597-603.
17. Herlitz H, Harris K, Risler T, Boner G, Bernheim J, Chanard J, et al: The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001;16(11):2158-2165.
18. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997; 126(12):955-959.
19. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei CL: Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102(5):546-551.
20. Ebbehoj E, Poulsen PL, Hansen KW, Knudsen ST, Molgaard H, Mogensen CE: Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 2002;45(7):965-975.
21. Owens PE, Lyons S, O'Brien E: Can heart rate predict blood pressure response to anti-hypertensive drug therapy? J Hum Hypertens 1998;12(4):229-233.
22. Soininen K, Gerlin-Piira L, Suihkonen J, Kyllonen T, Parviainen R, Kyllonen E, et al: A study of the effects of lisinopril when used in addition to atenolol. J Hum Hypertens 1992;6(4):321-324.
23. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955-1964.
24. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358(9290): 1305-1315.
25. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285(21):2719-2728.
26. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335(15):1107-1114.
27. Griffin KA, Picken MM, Bakris GL, Bidani AK: Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999;55(5):1849-1860.
28. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF: Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998;53(6):1559-1573.
29. Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000;14(3):295-301.
30. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61(3):1086-1097.
31. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135(2):73-87.
32. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156(3):286-289.
33. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-860.
34. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29(3):744-750.
35. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50(5):1641-1650.
36. Hillege HL, Fidler V, Diercks GF, Van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106(14):1777-1782.
37. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286(4): 421-426.
38. Bakris GL, Griffin KA, Picken MM, Bidani AK: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997;15(10):1181-1185.
39. Bakris GL: A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001; 161(22):2661-2667.
40. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54(4):1283-1289.
41. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M: Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria: a randomized cross-over study. Nephron 1998;80(2):175-182.
42. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283(15):1967-1975.
43. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003.
44. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-153.
45. Bakris G, Weir M, for the SHIELD Trial Investigators: Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003;5(3):202-209.
46. Owens PE, Lyons S, O'Brien E: Can heart rate predict blood pressure response to anti-hypertensive drug therapy? J Hum Hypertens 1998;12(4):229-233.
47. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667-1675.
48. Bakris GL, Slataper R, Vicknair N, Sadler R: ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994;8(1):2-6.
49. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131(9):660-667.
50. Rodby RA, Firth LM, Lewis EJ: An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996;19(10):1051-1061.
51. Hogan TJ, Elliott WJ, Seto AH, Bakris GL: Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002; 20(1):37-47.
52. Anderson AN, Wessels F, Moodley I, Kropman K: AT1 receptor blockers: cost-effectiveness within the South African context. S Afr Med J 2000;90(5):494-498.
53. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59(6):2282-2289.
54. Sica DA, Bakris GL: Type 2 diabetes: RENAAL and IDNT - the emergence of new treatment options. J Clin Hypertens (Greenwich) 2002;4(1):52-57.